Caris Life Sciences submitted an application to the New York State Department of Health for CLEP authorization to run its Caris Assure blood-based genomic profiling test on specimens from New York. The review will be conducted by the Wadsworth Center, aligning the assay’s availability with state-level laboratory evaluation requirements. Caris Assure uses circulating nucleic acid sequencing to analyze whole-exome and whole-transcriptome features across 22,000 genes, supporting tumor alterations, clonal hematopoiesis, inherited variants, pharmacogenomics, microsatellite instability, and tumor mutational burden. The filing formalizes an access expansion strategy for the company’s molecular profiling suite. Financially, Caris has leaned heavily on molecular profiling services, which were described as the drivers behind major revenue growth in recent quarters. A CLEP authorization outcome would therefore have direct implications for volume and commercial uptake. Stakeholders will watch for the review timeline, any technical validation requirements from Wadsworth, and subsequent rollout milestones in New York given Caris’s stated focus on compliance and patient-facing rigor.